Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1034148-04-3

AZD5423 is a potent and selective non-steroidal glucocorticoid receptor modulator (SGRM) characterized by its high affinity and selectivity for the glucocorticoid receptor. It is developed for the treatment of inflammatory diseases, offering a promising alternative to traditional glucocorticoids with reduced systemic exposure and metabolic activation. AZD5423 has demonstrated potent anti-inflammatory effects and a favorable safety profile in preclinical studies, positioning it as a promising candidate for managing inflammatory conditions.

1034148-04-3 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1034148-04-3 Structure

  • Basic information

    1. Product Name: AZD5423
    2. Synonyms: AZD5423;2,2,2-trifluoro-n-[(1r,2s)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(3-methoxyphenyl)propan-2-yl]acetamide
    3. CAS NO:1034148-04-3
    4. Molecular Formula: C25H21F4N3O3
    5. Molecular Weight: 487.4461528
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1034148-04-3.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: AZD5423(CAS DataBase Reference)
    10. NIST Chemistry Reference: AZD5423(1034148-04-3)
    11. EPA Substance Registry System: AZD5423(1034148-04-3)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1034148-04-3(Hazardous Substances Data)

1034148-04-3 Usage

Uses

Used in Pharmaceutical Industry:
AZD5423 is used as an anti-inflammatory agent for the treatment of inflammatory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Its high affinity and selectivity for the glucocorticoid receptor, along with reduced systemic exposure and metabolic activation, contribute to its potential for improved therapeutic benefits and reduced side effects compared to traditional glucocorticoid therapies. This makes AZD5423 a valuable asset in the development of novel treatments for inflammatory conditions.

Check Digit Verification of cas no

The CAS Registry Mumber 1034148-04-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,4,1,4 and 8 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1034148-04:
(9*1)+(8*0)+(7*3)+(6*4)+(5*1)+(4*4)+(3*8)+(2*0)+(1*4)=103
103 % 10 = 3
So 1034148-04-3 is a valid CAS Registry Number.

1034148-04-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name AZD-5423

1.2 Other means of identification

Product number -
Other names 2,2,2-trifluoro-N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(3-methoxyphenyl)propan-2-yl]acetamide

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1034148-04-3 SDS

1034148-04-3Relevant articles and documents

Self-assembled asymmetric catalyst engaged in a continuous-flow platform: An anti -selective catalytic asymmetric nitroaldol reaction

Hashimoto, Kazuki,Kumagai, Naoya,Shibasaki, Masakatsu

, p. 3496 - 3499 (2014)

An anti-selective catalytic asymmetric nitroaldol reaction was manifested in a continuous-flow platform. The requisite Nd/Na heterogeneous catalyst was readily prepared by self-assembly of an amide-based chiral ligand, NdO 1/5(OiPr)13/5, NaHMDS, and a multiwalled carbon nanotube without covalent linkage. A stainless-steel column filled with the Nd/Na catalyst was incorporated in a flow system to promote the nitroaldol reaction with high stereoselectivity. The flow system with the heterogeneous catalyst obviated the quenching operation, and the cooling system was minimized.

Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases

Hemmerling, Martin,Nilsson, Stinabritt,Edman, Karl,Eirefelt, Stefan,Russell, Wayne,Hendrickx, Ramon,Johnsson, Eskil,K?rrman M?rdh, Carina,Berger, Markus,Rehwinkel, Hartmut,Abrahamsson, Anna,Dahmén, Jan,Eriksson, Anders R.,Gabos, Balint,Henriksson, Krister,Hossain, Nafizal,Ivanova, Svetlana,Jansson, Anne-Helene,Jensen, Tina J.,Jerre, Anders,Johansson, Henrik,Klingstedt, Tomas,Lepist?, Matti,Lindsj?, Martin,Mile, Irene,Nikitidis, Grigorios,Steele, John,Tehler, Ulrika,Wissler, Lisa,Hansson, Thomas

, p. 8591 - 8605 (2017/11/03)

A class of potent, nonsteroidal, selective indazole ether-based glucocorticoid receptor modulators (SGRMs) was developed for the inhaled treatment of respiratory diseases. Starting from an orally available compound with demonstrated anti-inflammatory activity in rat, a soft-drug strategy was implemented to ensure rapid elimination of drug candidates to minimize systemic GR activation. The first clinical candidate 1b (AZD5423) displayed a potent inhibition of lung edema in a rat model of allergic airway inflammation following dry powder inhalation combined with a moderate systemic GR-effect, assessed as thymic involution. Further optimization of inhaled drug properties provided a second, equally potent, candidate, 15m (AZD7594), that demonstrated an improved therapeutic ratio over the benchmark inhaled corticosteroid 3 (fluticasone propionate) and prolonged the inhibition of lung edema, indicating potential for once-daily treatment.

CRYSTALLINE FORM OF INDAZOLYL AMIDE DERIVATIVES FOR THE TREATMENT GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS

-

Page/Page column 37-38, (2013/03/26)

Crystalline forms of 2,2,2-trifluoro-N-[(lR,2S)-l-[l-(4-fluorophenyl)in- dazol-5-yl]oxy-l-(3-methoxyphenyl)propan-2-yl]acetamide, processes for obtaining them, pharmaceutical intermediates used in their manu? facture, pharmaceutical compositions containing them, and their use in medical treatment.

INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS

-

Example 6, (2008/12/06)

Compounds of formula (I): The present invention relates to novel indazolyl ester or amide derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1034148-04-3